<DOC>
	<DOCNO>NCT02573077</DOCNO>
	<brief_summary>This observational , prospective , non-interventional study include cancer patient need treatment hyponatraemia secondary SIADH . Patients prescribed treatment ( ) accord clinical practice regardless patient participation study . The purpose NIS collect additional scientific clinical information help describe characteristic cancer patient hyponatraemia secondary SIADH , current management hyponatremia , therapy keep control serum [ Na+ ] guideline management population Italy .</brief_summary>
	<brief_title>An Observational Study Measuring Outcomes Cancer Patients Treated Moderate Severe Hyponatremia Italy</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<criteria>1 . Age &gt; = 18 year ; 2 . Male female patient cytologically histologically documented cancer diagnosis ; 3 . Moderate severe hyponatremia : Na+ level cut : [ Na+ ] &lt; 130 mmol/L ; 4 . Physician diagnose Moderate severe hyponatremia secondary SIADH ( clinical laboratory determine per normal routine practice treat physician ) ; 5 . No use diuretic agent within week prior evaluation ; 6 . Willingness participate study ; subject must give write consent participate . 1 . Use concomitant medication include demeclocycline and/or urea , combination fluid restriction ; 2 . Subject currently participate clinical trial investigational medicinal product aim treat cause symptom hyponatremia ; 3 . Life expectancy low 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hyponatremia due SIADH</keyword>
	<keyword>Cancer</keyword>
</DOC>